An optimised anti-cancer vaccine
ColoAd1 is a highly potent broad-spectrum anti-cancer therapeutic capable of destroying tumour cells at minute concentrations. It is a unique oncolytic vaccine developed using the evolutionary principle of natural selection to generate a vaccine with optimal anti-cancer properties.
Originally developed in collaboration with Bayer Schering, ColoAd1 is our lead candidate using the directed evolution process. The Evolve study is a phase 1/2 clinical study that is currently underway and is recruiting patients with metastatic cancer.
More Info »